Please contact us for more information or to learn if you are eligible to participate.
This study aims to evaluate the safety and tolerability of MK-1654 compared to palivizumab as assessed by the proportion of participants experiencing adverse events (AEs).
Dynio Honrubia, MD
Luis Cantu Jr.
Type of Trial